Transurethral Thermodilatation vs. Prostatic Urethral Lift for Moderate-to-Severe BPH
NCT: NCT07759752 · NOT_YET_RECRUITING
Brief Summary
This clinical trial aims to determine whether Prolieve® (microwave with balloon dilation) is as effective as UroLift® (prostate implants) for treating moderate-to-severe lower urinary tract symptoms in men aged 50-80 with enlarged prostates (BPH) who have failed oral medications. The main questions are: 1. Is Prolieve non-inferior to UroLift in improving IPSS symptom scores at 3 months? 2. Does Prolieve cause less pain and avoid the need for injected anaesthesia? Researchers will compare Prolieve (LA urethral gel only, no injections) against UroLift (LA urethral gel with or without local anaesthetic injection) to see if Prolieve offers similar relief with better tolerability. Participants will stop their BPH medications for 2-4 weeks, undergo one of the two same-day office procedures, and attend follow-ups at 1, 3, 6, and 12 months for symptom scores, flow tests, and bladder scans.
Frequently Asked Questions
What is Transurethral Thermodilatation vs. Prostatic Urethral Lift for Moderate-to-Severe BPH?
Transurethral Thermodilatation vs. Prostatic Urethral Lift for Moderate-to-Severe BPH is a clinical trial registered under NCT07759752. Current status: NOT_YET_RECRUITING.
What is the status of NCT07759752?
The current status of NCT07759752 (Transurethral Thermodilatation vs. Prostatic Urethral Lift for Moderate-to-Severe BPH) is: NOT_YET_RECRUITING.
When did Transurethral Thermodilatation vs. Prostatic Urethral Lift for Moderate-to-Severe BPH start?
Transurethral Thermodilatation vs. Prostatic Urethral Lift for Moderate-to-Severe BPH started on 2026-08-06.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.